Overview

Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)

Status:
Completed
Trial end date:
2005-12-28
Target enrollment:
0
Participant gender:
All
Summary
This trial is conducted in Japan. To investigate the long-term efficacy as assessed by change in fat mass and safety after 48 weeks of treatment of Growth Hormone in adults with Growth Hormone Deficiency, comparing two different treatment regiments.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Hormones
Criteria
Inclusion Criteria:

- Subjects who completed GHLiquid-1518.

- If the subject has a history of treatment for a tumor of pituitary or peripheral site,
two years or more have to be passed since completion of surgery, radiotherapy or other
treatment, and recurrence of the underlying disease to be excluded.

- Appropriate replacement therapy has been administered for more than 24 weeks for the
treatment of other pituitary hormone deficiencies.

Exclusion Criteria:

- Subject with a history of acromegaly.

- Subject with diabetes mellitus.

- Subject suffering from malignancy.

- Several medical conditions